Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Mark_A._Goldsmith
|
| gptkbp:focus |
oncology
precision medicines |
| gptkbp:foundedYear |
2014
|
| gptkbp:fullName |
gptkb:Revolution_Medicines,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Redwood_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
RVMD
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:products |
gptkb:PI3Kα_Inhibitors
RAS(ON) Inhibitors |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:RVMD
|
| gptkbp:website |
https://www.revmed.com/
|
| gptkbp:bfsParent |
gptkb:Revolution_Medicines
|
| gptkbp:bfsLayer |
6
|